A Phase 1 Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2014
At a glance
- Drugs Gemcitabine; Tremelimumab
- Indications Pancreatic cancer
- Focus Adverse reactions; Pharmacogenomic
- 05 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.
- 08 Aug 2011 Actual end date (Aug 2011) added as reported by ClinicalTrials.gov.
- 08 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.